Abstract
Over the past few years, the role of immunotherapy in colorectal cancer (CRC) has expanded, specifically in subsets of CRC with microsatellite instability (MSI) for which newer agents, such as programmed death-1 (PD-1) inhibitors, are efficacious. While other immunotherapeutic agents are more immature in development, they have the potential to enhance the efficacy of PD-1 inhibitors and play a role in the treatment algorithm for all subsets of CRC patients. In this review, we will discuss immunotherapeutic agents in development in patients with CRC. We will review the later phase studies that elucidate the role of immunotherapy in CRC and provide hope for changing the treatment paradigm for CRC in the future.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 170-179 |
| Number of pages | 10 |
| Journal | Journal of Gastrointestinal Oncology |
| Volume | 9 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 1 2018 |
Funding
Funding: SP Arora: NCI P30CA054174, NIA P30AG044271. D Mahalingam: NCI P30CA054174
Keywords
- Checkpoint inhibition
- Colorectal cancer (CRC)
- Immunotherapy
- Mismatch repair
- Programmed death-1 (PD-1)
ASJC Scopus subject areas
- Gastroenterology
- Oncology
